BETA irradiation of the eye remains relatively unemployed because of inconvenience, practical difficulties, and, in some instances, potential radiation hazard to the operator or to the patient's lens, or occasionally to both; but, because this form of superficial radiation therapy is both safe and effective when used properly in the conditions for which it is indicated and since it has no therapeutic equivalent in some instances, the continuing search for an improved ophthalmic applicator has led to the use of artificially radioactive isotopes.
Radioactive strontium (Sr90) was chosen for the source material by Friedell and his associates,1 who were the first to use this fission product in an applicator for ophthalmic use. Following the lead of this laboratory model, commercial physicists recently developed a clinical model, the RA-1 Medical Applicator.2
The effects of clinical treatments with new applicators of this type are certain to be somewhat unpredictable
WILSON FM, WILSON JW. RADIOACTIVE STRONTIUM THERAPY OF THE EYE: Corneal Biostandardization and Evaluation of an Applicator for Use in Ophthalmology. AMA Arch Ophthalmol. 1952;48(6):686–695. doi:10.1001/archopht.1952.00920010698003
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: